Mohammad Baig, MD
Endocrinology · Tampa, FLNPI 1982640249
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novo Nordisk at 33.0% of the total. 2025 is the largest year on record at $918, 4.9 times the $186 reported in 2019.
Across 117 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$778
- Bayer$300
- Abbott$208
- Corcept Therapeutics$181
- Insulet Corporation$127
- Amgen$98
- plus $668 from 18 others
What the payments were for
- Food & beverage$2,32098%
- Education$392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $778 |
| Bayer | 8 | $300 |
| Abbott | 7 | $208 |
| Corcept Therapeutics | 5 | $181 |
| Insulet Corporation | 7 | $127 |
| Amgen | 5 | $98 |
| Medtronic | 4 | $84 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Lilly USA, LLC | 4 | $74 |
| AbbVie | 4 | $60 |
| Dexcom, Inc. | 3 | $48 |
| Sequel Med Tech, LLC | 2 | $46 |
| Lifescan, Inc. | 3 | $42 |
| Boehringer Ingelheim | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Cequr Corporation | 1 | $21 |
| Novartis | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Renalytix AI, Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| GSK | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$125
- Kerendia$122
- RYBELSUS$121
- Korlym$115
- FreeStyle Libre Pro$106
How this compares
Too few endocrinology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 566 | $603,037 |
| TrulicityDulaglutide | 419 | $487,571 |
| JardianceEmpagliflozin | 185 | $148,541 |
| MounjaroTirzepatide | 58 | $88,290 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 49 | $81,061 |
| Tresiba Flextouch U-100Insulin Degludec | 135 | $77,783 |
| JanuviaSitagliptin Phosphate | 85 | $69,225 |
| FarxigaDapagliflozin Propanediol | 81 | $59,085 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $41,336 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 270 | $39,668 |
| RybelsusSemaglutide | 31 | $35,033 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $34,427 |
| JanumetSitagliptin Phos/Metformin Hcl | 48 | $27,439 |
| NovologInsulin Aspart | 120 | $26,529 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $24,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp, Levemir | $778 | $689,316759 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $74 | $588,546538 claims |
| Boehringer IngelheimJardiance, Tradjenta | $35 | $167,488218 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $35 | $48,347159 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $8,3221,042 claims |
| AbbVieSynthroid | $60 | $5,24861 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Tampa
- Vivian RoseCoral Springs$14K
- Bryan VinikBoca Raton$13K
- Renee FreedmanBoca Raton$10K
- Rolando RodriguezBoca Raton$8K
- Carlos ZapataTallahassee$5K
- Michael FiliMiami$4K
- Rodolfo Perez LopezHialeah$3K
- Myat MyintHudson$182
- Kathryn JonesBoca Raton$142
- Alan BalsamDeerfield Beach$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.